<DOC>
	<DOC>NCT01573468</DOC>
	<brief_summary>This study is being performed to evaluate the efficacy and safety of capecitabine in combination with tesetaxel versus capecitabine in combination with placebo as second-line treatment for patients with gastric cancer.</brief_summary>
	<brief_title>Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Key inclusion criteria: 1. Histologically or cytologically confirmed gastric adenocarcinoma, including gastric or gastroesophagealjunction adenocarcinoma (Histologically confirmed adenocarcinoma of the lower esophagus acceptable with radiographic or endoscopic documentation of gastroesophagealjunction or proximalstomach involvement.) 2. Measurable disease (revised RECIST) based on computed tomography, or nonmeasurable disease 3. ECOG performance status 0 or 1 4. Treatment with only 1 prior regimen (as firstline therapy) that must have included a fluoropyrimidine and a platinumcontaining agent (Prior adjuvant or neoadjuvant chemotherapy acceptable provided 6 months elapsed between the end of this therapy and the start of firstline therapy.) 5. Disease progression after the start of the 1 prior regimen based on computed tomography 6. Adequate bone marrow, hepatic, and renal function 7. Ability to swallow an oral soliddosage form of medication Key exclusion criteria: 1. Squamous cell gastric carcinoma 2. Boneonly metastatic disease 3. History or presence of brain metastasis or leptomeningeal disease 4. Operable gastric or gastroesophagealjunction cancer 5. HER2positive disease if the patient has not previously been treated with an antiHER2 agent 6. Uncontrolled diarrhea, nausea, or vomiting 7. Known malabsorptive disorder 8. Significant medical disease other than gastric cancer 9. Presence of neuropathy &gt; Grade 1 (NCI Common Toxicity Criteria) 10. Prior treatment (including adjuvant therapy) with a taxane or other tubulintargeted agent (indibulin, eribulin, etc.) 11. Prior radiation therapy to more than 25% of the bone marrow 12. Need to continue any regularlytaken medication that is a potent inhibitor or inducer of the CYP3A pathway 13. Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>